logo
Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all
High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens
Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection
Epidemiology and outcomes of hepatitis C infection in elderly US Veterans
Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach
Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy
Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma
Hepatitis C-induced hepatocyte apoptosis following liver transplantation is enhanced by immunosuppressive agents